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in advanced stages of AMD disease, and (2) as the visual acu-
ity of AMD patients decreased, the olfactory abilities of these 
patients worsened.  Conclusion: This study demonstrated 
that AMD had significant negative effects on all orthonasal 
olfactory tasks, particularly in advanced stages. Similar to 
other neurodegenerative diseases, odor discrimination and 
identification seemed to be more affected than odor detec-
tion threshold tasks.  © 2015 S. Karger AG, Basel 
 Introduction 
 Olfactory dysfunction is a common symptom of many 
neurodegenerative diseases  [1] . Impairment of olfaction 
may develop at the early stage of Alzheimer’s disease 
(AD), Parkinson’s disease (PD) and other synucleinopa-
thies and mild cognitive impairment  [2, 3] . Olfactory dys-
function in mild cognitive impairment is a precursor sign 
of its progression to dementia  [4] . Smell dysfunction is 
one of the most common nonmotor signs of PD that may 
develop in 90% of cases. Impairment of olfaction is also a 
preclinical sign of PD  [5] . Recently, olfactory dysfunction 
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 Abstract 
 Background: Olfactory dysfunction is a common symptom 
of many neurodegenerative diseases, and age-related mac-
ular degeneration (AMD) is a late-onset neurodegenerative 
disease.  Objective: Thus, the aim of this study was to inves-
tigate olfactory functions in patients with AMD.  Methods: A 
total of 69 subjects with AMD and 69 age- and sex-matched 
healthy controls were enrolled. After a complete ophthalmic 
evaluation, the AMD patients were subclassified as early- 
and late-stage AMD. Psychophysical testing of olfactory 
function was performed using the validated Sniffin’ Sticks 
test.  Results: This study was carried out in 138 subjects, with 
a mean age of 74.3 ± 8.9 years (range 51–89). The current in-
vestigation showed the following two major findings: (1) pa-
tients with AMD had decreased olfactory abilities, especially 
in odor discrimination and odor identification, even at early 
stages compared to controls, whereas patients had de-
creased olfactory abilities in all subtasks of olfactory testings 
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was thought to be an early marker for the diagnosis of 
neurodegenerative diseases. The pathological changes in 
neurodegenerative diseases may involve the olfactory ep-
ithelium, olfactory bulb/tract and primary olfactory cor-
tices. Damage to cholinergic, serotonergic and noradren-
ergic systems may also contribute to olfactory dysfunc-
tion  [6] .
 Age-related macular degeneration (AMD) is a late-on-
set neurodegenerative disease that affects photoreceptors, 
retinal pigment epithelium, Bruch’s membrane, and the 
choroid. It is the leading cause of irreversible blindness 
among the elderly in industrialized nations  [7] . The patho-
genesis of AMD is multifactorial and is thought to involve 
a complex interaction between genetic and other factors 
such as oxidative stress, hydrodynamic alterations, hemo-
dynamic changes, inflammatory influences, and apoptot-
ic factors  [8] . AMD shares common similar pathways of 
pathogenesis and common risk factors (aging, smoking, 
oxidative stress, chronic inflammation, intra- and extra-
cellular deposits) with neurodegenerative disorders. Ol-
factory involvement in AD and PD has been well studied 
and identified. However, to the best of our best knowl-
edge, there have been no studies to date relating to olfac-
tory involvement in AMD. We may expect olfactory dys-
function in AMD because of its many similarities with AD 
and PD. Thus, the aim of this study was to investigate the 
olfactory functions in patients with AMD.
 Materials and Methods 
 Study Design 
 This prospective, cross-sectional comparative study was per-
formed at the Ophthalmology and Neurology Departments of 
Gulhane Military Medical Academy Haydarpaşa Training Hospi-
tal. All investigations were performed in accordance with the Dec-
laration of Helsinki on biomedical studies involving human sub-
jects, and informed consent was obtained from all participants be-
fore the study began. This study was approved by the Clinical 
Research Ethics Committee of Haydarpaşa Numune Education 
and Research Hospital.
 Subjects 
 A total of 69 subjects with AMD and 69 age- and sex-matched 
healthy controls were enrolled. All subjects underwent a complete 
ophthalmological examination, including logMAR best-corrected 
visual acuity, intraocular pressure measurement with a pneumatic 
tonometer, slit-lamp biomicroscopy, dilated fundus examination, 
fundus photography, and optical coherence tomography. After de-
tailed ophthalmic examination, patients in the AMD group were 
subclassified as early AMD and late AMD according to the criteria 
described by the International Age-Related Maculopathy Epidemi-
ologic Study Group  [9] . For subjects with asymmetric AMD lesions 
in both eyes, AMD was defined according to the more affected eye. 
Rhinological examination, including nasal endoscopy and neuro-
logical examination, was also performed on all subjects. Exclusion 
criteria included the following: history of ocular diseases such as 
glaucoma, uveitis, optic neuropathy, and acquired or hereditary 
retinal diseases, history of upper respiratory infections within the 
previous 3 weeks, taste and smell disorders, sinonasal disorders (na-
sal polyps, chronic rhinosinusitis, congestion, allergic rhinitis), 
asthma, malignancy, head trauma, neurological and psychiatric 
disorders (AD, PD, epilepsy, schizophrenia, history of stroke), met-
abolic and endocrine disorders (diabetes mellitus, hypogonadism), 
or current history of smoking more than 5 cigarettes per day.
 Orthonasal Olfactory Testing 
 Psychophysical testing of olfactory function was performed us-
ing with Sniffin’ Sticks test, where odorants were presented in 
commercially available felt-tip pens (Sniffin’ Sticks; Burghart, We-
del, Germany)  [10, 11] . This test was validated widely in Europe 
and also in our population  [12, 13] . For odor presentation the cap 
of the pen was removed by the experimenter for approximately 3 s, 
and the tip of the pen was placed approximately 1–2 cm in front of 
the nostrils. The test consists of one threshold and two supra-
threshold subtests, namely a test for thresholds of n-butanol, a test 
for odor discrimination (16 triplets with 2 different odors) and one 
for odor identification (16 common odors, presented in a 4-alter-
native, forced-choice procedure). The maximum TDI (threshold, 
discrimination and identification) score of each subtest was 16, 
resulting in a maximum composite score of 48  [14] . The normal 
values for the TDI composite score are >30.3, with a cutoff between 
anosmia and hyposmia at 16.5  [12] .
 Statistical Analysis 
 Data analyses were performed using SPSS 21.0 (Statistical 
Package for Social Sciences, SPSS Inc., Chicago, Ill., USA). The 
normal distribution of the considered variables was first evaluated 
using the Shapiro-Wilk test. Data are presented as the mean ± stan-
dard deviation for continuous variables and number of cases for 
categorical variables. Independent samples t test was used to com-
pare the means between AMD and control groups. The differenc-
es between the groups (control, early AMD and late AMD) were 
analyzed by analysis of variance (ANOVA) or χ 2 test, as appropri-
ate. Tukey’s post hoc tests were also performed to identify the dif-
ferences among the groups. The visual acuity of the more affected 
eye was used for statistical analysis. To explore olfactory function 
in relation to the continuous variables measured in this study, data 
were submitted to a multivariate ANOVA using the general linear 
model. Pearson’s correlation coefficient was performed to evaluate 
the correlation between the visual acuity of patients with AMD and 
olfactory testing. A p value <0.05 was considered to be statistically 
significant.
 Results 
 This study was carried out in 138 subjects, with a mean 
age of 74.3 ± 8.9 years (range 51–89). The subjects were 
divided into two groups: 69 patients with AMD and 69 
age- and sex-matched healthy controls.  Table 1 gives the 
descriptive statistics of each of the variables of the groups.
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 As shown in  table 1 the differences in terms of odor 
threshold, odor discrimination, odor identification, and 
TDI scores between the control and AMD groups were 
significant. The scores of olfactory testing of the AMD 
group were lower than those in the control group. Also, 
as expected, a significant decrease was detected in the 
AMD group in terms of visual acuity compared to con-
trols.
 After an ophthalmic evaluation, the AMD subjects 
were further classified as early and late AMD. Statistical 
analysis was performed between these groups – early 
AMD, late AMD and control groups.  Tables 2 and  3 give 
the descriptive statistics of this analysis. There was no sig-
nificant difference between the groups in terms of age and 
gender (p = 0.69 and p = 0.08, respectively). There were 
significant differences between the study groups in terms 
 Table 1.  Descriptive statistics of results from olfactory testing and measurement of visual acuity according to 
grouping: patients with AMD and controls
Characteristics AMD group (n = 69) Control group (n = 69) p value
Age, years 74.6±9.1 74±8.8 0.7
Gender (M/F) 32/37 32/37
Odor threshold score 9.4±2.4 10.1±1.7 0.03
Odor discrimination score 11.3±2.3 12.8±1.5 <0.001
Odor identification score 8.7±2.6 11.9±1.8 <0.001
TDI score 29.3±6.9 34.8±4.2 <0.001
Visual acuity (logMAR) 1.0±0.5 0.1±0.12 <0.001
 p value: independent samples t test.
 Table 2.  Descriptive statistics of results from olfactory testing and measurement of visual acuity after staging 
AMD
Characteristics Early-stage AMD
(n = 25)
Advanced-stage 
AMD (n = 44)
Control group
(n = 69)
p value
Age, years 71.4±9.8 76.5±8.3 74±8.8 0.691
Gender (M/F) 16/9 16/28 32/37 0.082
Odor threshold score 9.9±2.7 9.1±2.3 10.1±1.7 0.021
Odor discrimination score 11.5±2.3 11.1±2.3 12.8±1.5 <0.0011
Odor identification score 8.9±2.7 8.5±2.5 11.9±1.8 <0.0011
TDI score 30.4±7.4 28.7±6.7 34.8±4.2 <0.0011
Visual acuity (logMAR) 0.73±0.5 1.2±0.45 0.1±0.12 <0.0011
 1 ANOVA with Tukey’s post hoc test. 2 χ2 test.
 Table 3.  p values according to the results of Tukey’s post hoc test for the comparison of the study groups in terms 
of olfactory testing and visual acuity
I–II I–III II–III
Odor threshold score 0.2 0.9 0.02
Odor discrimination score 0.7 0.02 <0.001
Odor identification score 0.8 <0.001 <0.001
TDI score 0.5 0.004 <0.001
Visual acuity (logMAR) <0.001 <0.001 <0.001
 Group I: early-stage AMD; group II: late-stage AMD; group III: controls.
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of all the subtasks of olfactory testing and visual acuity. 
When post hoc tests were performed, it was detected that 
the late AMD group had significantly lower scores in odor 
threshold testing compared to the control group (p  = 
0.02). However, we did not find a significant difference 
either between the early AMD and control groups or be-
tween the early and late AMD groups in terms of odor 
threshold scores (p = 0.9 and p = 0.2, respectively).
 When the post hoc tests were performed for odor dis-
crimination, odor identification and TDI scores, we 
found that both the early and late AMD groups had sig-
nificantly lower scores compared to controls (p  = 0.02 
and p < 0.001, respectively, for odor discrimination; p < 
0.001 and p < 0.001, respectively, for odor identification; 
p = 0.004 and p < 0.001, respectively, for TDI). However, 
no difference was detected between the early and late 
AMD groups in terms of odor discrimination, identifica-
tion and TDI scores (p = 0.7, p = 0.8 and p = 0.5, respec-
tively).
 Moreover, a multivariate analysis was performed for 
evaluating the effects of independent variables (age and 
logMAR) on dependent variables (Sniffin’ Sticks sub-
tests). Both age and logMAR scores had a significant ef-
fect on olfactory scores (p = 0.002 and p < 0.001, respec-
tively). Also, the correlation analyses were performed 
with Pearson’s test and we found a negative correlation 
between visual acuity and olfactory testing of the follow-
ing: odor threshold, odor discrimination, odor identifica-
tion, and TDI scores (p < 0.01, r = –0.32; p < 0.001, r = 
–0.46; p < 0.001, r = –0.6 and p < 0.001, r = –0.5, respec-
tively;  fig. 1 ).
 Discussion 
 The current investigation showed the following two 
major findings: (1) patients with AMD had decreased ol-
factory abilities, especially in odor discrimination and odor 
identification, even at early stages compared to controls, 
whereas AMD patients had decreased olfactory abilities in 
all subtasks of olfactory testing in advanced stages of AMD 
disease, and (2) as the visual acuity of AMD patients de-
creased, the olfactory abilities of these patients worsened.
 To the best of our knowledge, this study was the first 
regarding the association between olfactory dysfunction 
and AMD. There are several possible mechanisms for the 
association between AMD and olfactory impairment. Ol-
factory dysfunction is known to be a common and early 
symptom of many neurodegenerative diseases, particu-
larly PD and AD  [1] . AMD shares common similar path-
ological risk factors with PD and AD, including aging, 
smoking, oxidative stress, chronic inflammation, and in-
tra- and extracellular deposits. The results of recent stud-
ies on the diseases of aging such as AMD, PD, AD, and 
atherosclerosis demonstrated that they have a common 
feature – the buildup of extracellular deposits (containing 
many shared molecular constituents) that contribute to 
their pathogenesis and progression. An association is ex-
plained with the local activation of proinflammatory 
pathways, thereby leading to the concurrent deposition of 
activated complement components, acute phase reac-
tants, immune modulators, and other inflammatory me-
diators in these degenerative diseases  [15–18] .
 The neuropathological changes that cause these neuro-
degenerative diseases might also affect the olfactory epi-
thelium, olfactory bulb/tract, primary olfactory cortices, 
and their secondary targets by increasing the accumula-
tion of pathological proteins, oxidative stress and neuroin-
flammation  [1] . Oxidative stress plays an important role in 
neurodegeneration, and cases of increased oxidative dam-
age within the olfactory neuroepithelium of patients with 
AD have been reported  [19] . Hawkes et al.  [20] examined 
the functional and morphological aspects of olfaction in 
motor neuron disease. The pathological results showed 
marked accumulation of lipofuscin in olfactory neurons 
compared to controls. Lipofuscin refers to a diverse group 
of autofluorescent lipid and protein aggregates which is 
derived from the imbalance between the production of 
damaged cellular components and degradation. Its pres-
ence in increased amounts is associated with oxidative tis-
 Fig. 1. Visual acuity scores (logMAR) had a significant correlation 
with the sum score of olfactory testing (TDI) in patients with 
AMD. Scatter plot graph modeling (black – controls; red – early-
stage AMD; green – late-stage AMD; color in online version only).
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
0
0.5
1.0
1.5
2.0
10 15 20 25 30 35 40 45
Vi
su
al
 a
cu
ity
 (l
og
M
AR
)
Sum score of olfactory testing (TDI)
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:1
6:
18
 A
M
 Age-Related Macular Degeneration and 
Olfaction 
Neurodegener Dis 2015;15:219–224
DOI: 10.1159/000381216
223
sue damage. Lipofuscin granules can contain toxic com-
pounds such as N-retinyl-N-retinylidene ethanolamine 
(A2E) which can lead to cellular dysfunction  [21] . Lipo-
fuscin also plays an important role in AMD pathogenesis. 
Lipofuscin accumulates in the retinal pigment epithelium 
cells and is reported to photochemically generate reactive 
oxygen species, including singlet oxygen, hydrogen perox-
ide and superoxide anions that may increase oxidative 
damage in the retinal pigment epithelium  [8] .
 Nitric oxide (NO) is an important cellular signaling 
molecule that acts as a neuromodulator. However, excess 
NO is able to form other reactive intermediates, including 
nitrite and peroxynitrite, which can cause neurodegen-
eration by increasing oxidative and nitrosative stress  [22] . 
Murdaugh et al.  [23] reported that 3-nitrotyrosine (a neu-
rochemical marker of peroxynitrite) and nitrated A2E 
levels increase in human Bruch’s membrane with age. 
Yang et al.  [24] examined the age-related changes in 3-ni-
trotyrosine in the olfactory bulb of mice. They found in-
creased 3-nitrotyrosine expression in mitral and tufted 
cells in the olfactory bulb of aged mice. Taken together, 
these findings suggest that nitrosative stress in Bruch’s 
membrane and olfactory bulb may play a potential role in 
the pathogenesis of AMD and olfactory dysfunction.
 A meta-analysis study about the effect of AD and PD 
on olfaction indicated that AD and PD patients are more 
impaired in odor identification and discrimination than 
in odor threshold tasks. PD patients are more impaired in 
detection thresholds than AD patients, suggesting that 
PD patients are more impaired in low-level perceptual 
olfaction tasks, whereas AD patients are more impaired 
in higher-order olfactory tasks involving specific cogni-
tive processes  [25] . Our results resemble those of the me-
ta-analysis study.
 Since sensory problems may affect an older person’s 
ability to carry out routine activities that define social roles 
and quality of life, olfactory impairment is more impor-
tant for AMD patients. AMD patients have significantly 
more difficulty when shopping, managing money, prepar-
ing meals, performing light housework, and using the tele-
phone than community adults of similar age. Diminished 
vision is also associated with increases in hip fractures, 
falls, depression, physician visits, hospitalizations, and 
mortality  [26] . The sense of smell plays an important role 
in human daily life, for example, by alerting us against and 
attracting us toward odorous items, influencing food in-
take, and affecting interpersonal relations. Impairment of 
olfactory ability, therefore, leads to disturbances in impor-
tant areas, mainly in food enjoyment and in detecting 
harmful food, smoke and environmental hazards. Olfac-
tory impairment is also associated with depressive symp-
toms and poorer quality of life  [27] . Combined visual and 
smell disorder may cause more impairment of life quality.
 Conclusion 
 This study demonstrated that AMD had significant 
negative effects on all orthonasal olfactory tasks, particu-
larly in advanced stages. Similar to other neurodegenera-
tive diseases, odor discrimination and identification 
seemed to be more affected than odor detection threshold 
tasks.
 Potential limitations of our study should be men-
tioned. First, it was a case-control study with a small 
number of subjects. Second, we used only psychophysical 
tests for assessing the olfactory system. Electrophysiolog-
ical and imaging procedures could be used for assess-
ment. Further studies, with a large number of subjects, are 
needed to understand the relationship between visual and 
olfactory impairment in older patients.
 Disclosure Statement 
 The authors have no conflicts of interest to declare. 
 References 
 1 Attems J, Walker L, Jellinger KA: Olfactory 
bulb involvement in neurodegenerative dis-
eases. Acta Neuropathol 2014; 127: 459–475. 
 2 Huisman E, Uylings HB, Hoogland PV: A 
100% increase of dopaminergic cells in the ol-
factory bulb may explain hyposmia in Par-
kinson’s disease. Mov Disord 2004; 19: 687–
692. 
 3 Attems J, Lintner F, Jellinger KA: Olfactory 
involvement in aging and Alzheimer’s dis-
ease: an autopsy study. J Alzheimers Dis 2005; 
 7: 149–157. 
 4 Attems J, Jellinger KA: Olfactory tau pathology 
in Alzheimer disease and mild cognitive im-
pairment. Clin Neuropathol 2006; 25: 265–271. 
 5 Doty RL: Olfaction in Parkinson’s disease and 
related disorders. Neurobiol Dis 2012; 46: 
 527–552. 
 6 Kovacs I, Torok I, Zombori J, Kasa P: Cholin-
ergic structures and neuropathologic altera-
tions in the olfactory bulb of Alzheimer’s dis-
ease brain samples. Brain Res 1998; 789: 167–
170. 
 7 Klein R, Klein BE, Linton KL: Prevalence of 
age-related maculopathy. The Beaver Dam 
Eye Study. Ophthalmology 1992; 99: 933–943. 
 8 Ambati J, Ambati BK, Yoo SH, Ianchulev S, 
Adamis AP: Age-related macular degenera-
tion: etiology, pathogenesis, and therapeutic 
strategies. Surv Ophthalmol 2003; 48: 257–293. 
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:1
6:
18
 A
M
 Kar/Yildirim/Altundağ/Sonmez/Kaya/
Colakoglu/Tekeli/Cayonu/Hummel 
Neurodegener Dis 2015;15:219–224
DOI: 10.1159/000381216
224
 9 Bird AC, Bressler NM, Bressler SB, Chisholm 
IH, Coscas G, Davis MD, de Jong PT, Klaver 
CC, Klein BE, Klein R, et al: An international 
classification and grading system for age-re-
lated maculopathy and age-related macular 
degeneration. The International ARM Epide-
miological Study Group. Surv Ophthalmol 
1995; 39: 367–374. 
 10 Hummel T, Sekinger B, Wolf S, Pauli E, Ko-
bal G: ‘Sniffin’ Sticks’: olfactory performance 
assessed by the combined testing of odor 
identification, odor discrimination and ol-
factory threshold. Chem Senses 1997; 22: 39–
52. 
 11 Kobal G, Klimek L, Wolfensberger M, 
Gudziol H, Temmel A, Owen CM, Seeber H, 
Pauli E, Hummel T: Multicenter investiga-
tion of 1,036 subjects using a standardized 
method for the assessment of olfactory func-
tion combining tests of odor identification, 
odor discrimination, and olfactory thresh-
olds. Eur Arch Otorhinolaryngol 2000; 257: 
 205–211. 
 12 Hummel T, Kobal G, Gudziol H, Mackay-Sim 
A: Normative data for the ‘‘Sniffin’ Sticks’’ in-
cluding tests of odor identification, odor dis-
crimination, and olfactory thresholds: an up-
grade based on a group of more than 3,000 
subjects. Eur Arch Otorhinolaryngol 2007; 
 264: 237–243. 
 13 Tekeli H, Altundağ A, Salihoğlu M, Cayönü 
M, Kendirli MT: The applicability of the ‘Snif-
fin’ Sticks’ olfactory test in a Turkish popula-
tion. Med Sci Monit 2013; 19: 1221–1226. 
 14 Wolfensberger M, Schnieper I, Welge-Lussen 
A: ‘Sniffin’ Sticks’: a new olfactory test battery. 
Acta Otolaryngol 2000; 120: 303–306. 
 15 Anderson DH, Mullins RF, Hageman GS, 
Johnson LV: A role for local inflammation in 
the formation of drusen in the aging eye. Am 
J Ophthalmol 2002; 134: 411–431. 
 16 McGeer PL, McGeer EG: Inflammation and 
the degenerative diseases of aging. Ann NY 
Acad Sci 2004; 1035: 104–116. 
 17 Zipfel PF, Heinen S, Jozsi M, Skerka C: Com-
plement and diseases: defective alternative 
pathway control results in kidney and eye dis-
eases. Mol Immunol 2006; 43: 97–106. 
 18 Nowak JZ: Age-related macular degeneration 
(AMD): pathogenesis and therapy. Pharma-
col Rep 2006; 58: 353–363. 
 19 Perry G, Castellani RJ, Smith MA, Harris PL, 
Kubat Z, Ghanbari K, Jones PK, Cordone G, 
Tabaton M, Wolozin B, Ghanbari H: Oxida-
tive damage in the olfactory system in Al-
zheimer’s disease. Acta Neuropathol 2003; 
 106: 552–556. 
 20 Hawkes CH, Shephard BC, Geddes JF, Body 
GD, Martin JE: Olfactory disorder in motor 
neuron disease. Exp Neurol 1998; 150: 248–253. 
 21 Brunk UT, Terman A: Lipofuscin: mecha-
nisms of age-related accumulation and influ-
ence on cell function. Free Radic Biol Med 
2002; 33: 611–619. 
 22 Calabrese V, Bates TE, Stella AM: NO syn-
thase and NO-dependent signal pathways in 
brain aging and neurodegenerative disorders: 
the role of oxidant/antioxidant balance. Neu-
rochem Res 2000; 25: 1315–1341. 
 23 Murdaugh LS, Wang Z, Del Priore LV, Dillon J, 
Gaillard ER: Age-related accumulation of 3-ni-
trotyrosine and nitro-A2E in human Bruch’s 
membrane. Exp Eye Res 2010; 90: 564–571. 
 24 Yang MJ, Sim S, Jeon JH, Jeong E, Kim HC, 
Park YJ, Kim IB: Mitral and tufted cells are 
potential cellular targets of nitration in the ol-
factory bulb of aged mice. PLoS One 2013; 
 8:e59673. 
 25 Rahayel S, Frasnelli J, Joubert S: The effect of 
Alzheimer’s disease and Parkinson’s disease 
on olfaction: a meta-analysis. Behav Brain Res 
2012; 231: 60–74. 
 26 Gopinath B, Anstey KJ, Sue CM, Kifley A, 
Mitchell P: Olfactory impairment in older 
adults is associated with depressive symptoms 
and poorer quality of life scores. Am J Geriatr 
Psychiatry 2011; 19: 830–834. 
 27 Frasnelli J, Hummel T: Olfactory dysfunction 
and daily life. Eur Arch Otorhinolaryngol 
2005; 262: 231–235. 
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:1
6:
18
 A
M
